Upcoming Webinar
A Combination Treatment for Patients with Advanced Renal Cell Carcinoma
Date: August 13, 2026 | 2:00 PM
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
In this session, Jennifer Hasiak, PharmD (Hematology & Oncology Consultants), examines cabozantinib (CABOMETYX®) plus nivolumab (OPDIVO®) in first-line advanced renal cell carcinoma, bringing the clinical evidence into conversation with the day-to-day realities of monitoring, adverse-reaction management and patient education.
You’ll learn about:
- How the efficacy and safety data inform the use of cabozantinib plus nivolumab in first-line aRCC
- Key considerations when monitoring for select adverse reactions
- Approaches to managing certain adverse reactions associated with cabozantinib monotherapy, cabozantinib plus nivolumab, and nivolumab and hyaluronidase-nvhy (OPDIVO QVANTIG™)
- How patient education can support earlier communication and informed treatment management
- Resources available to support providers, patients and caregivers
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Additional Upcoming Webinars
Upcoming Webinar
Techs Talk Navigating OptumRx Audits & Validation Requests
August 12, 2026 | 3:00 PM
August 13, 2026 | 2:00 PM
